Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Neoplasm Metastasis 1

Interventions

Magnetic Resonance Spectroscopy 9gallium 68 PSMA-11 7Specimen Handling 42-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 4enzalutamide 2bicalutamide 2acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2Standard of Care 2Radiation 2Positron Emission Tomography Computed Tomography 2HhAntag691 2Abiraterone Acetate 268Ga-DKFZ-PSMA-11 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2xentuzumab 1trastuzumab biosimilar HLX02 1tislelizumab 1teprotumumab 1tazemetostat 1relugolix 1pertuzumab 1palbociclib 1olaparib 1niraparib 1gallium citrate 1eribulin 1entrectinib 1darolutamide 1cobimetinib 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Prostatic Neoplasms × Citric Acid × Clear all
NCT02391025 2023-06-18

Gallium-68 Citrate PET Used in Prostate Cancer

University of California, San Francisco

Phase EARLY_PHASE1 Completed
39 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡